Foto_Devicare_Inmave_webDevicare has signed an agreement with the company Inmave to market the family of Lit-Control® products in Colombia for the domiciliary control of frequent urological pathologies. Colombia is the second American country and the fourth globally, after Spain, Mexico and France, to distribute this first-in-class method.

The two companies have begun the regulation process with the Colombian National Institute for Medicine and Food Surveillance (INVIMA) with the support of ACCIÓ de Bogotá’s office. Lit-Control® is expected to reach patients at the end of 2017.

There are almost 4.5 million people in Colombia in chronic patient programmes, according to the Colombian Association of Integral Medicine Companies (ACEMI), a number that would increase since the Colombian Urology Society states that many pathologies are under-diagnosed. For example, out of every 10 patients with an overactive bladder, only 28% are diagnosed, and 16% of these receive treatment.

Colombia has renowned professionals, but lacks innovative medical technology,” explains Miquel González-Mut, International Business Development Manager at Devicare. The country’s government is aware of the problem and has promoted a renewal process of the health system aimed at relieving pressure and personalising treatment with actions such as opening 40 Primary Healthcare Facilities in Bogotá. The introduction of Lit-Control® fits perfectly with the state goals.

The products of the Lit-Control® family enable urinary pH to be managed and controlled at home not only for renal and urinary lithiasis, but also other pathologies with a high rate of recurrence, such as urinary infection, overactive bladder, painful bladder syndrome, interstitial cystitis and calcification of urinary catheters. Its introduction means the same for patients of these chronic urological diseases as self-control with glucometer and insulin meant for diabetics. It will also provide the medical community with better follow-up and patient control, as well as greater adherence to and effectiveness of the treatment.

Press release (English)

Press release (Catalan)